A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.
While RT-PCR is the current gold standard to confirm a SARS-CoV-2 infection, antigen rapid test (ART) for COVID-19 allows for quick detection of SARS-CoV-2 and thus fast triaging of infected patients requiring isolation at the population level, according to studies presented at ECCMID 2021.
Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.
Long-term care facility (LTCF) residents aged ≥65 years appeared to be protected from COVID-19 4–7 weeks after receiving their first dose of the ChAdOx1 nCoV-19 or BNT162b2 vaccine, according to a study presented at ECCMID 2021.
Patients with psoriasis taking the immunosuppressant methotrexate had low antibody responses to SARS-CoV-2 after receiving the first dose of Pfizer-BioNTech’s BNT162b2 vaccine but had shown T-cell responses, according to a study that was the first to look at T-cell responses in patients taking methotrexate.
Treatment with casirivimab/imdevimab combination therapy appears to be associated with a reduced risk of hospitalization or death compared with bamlanivimab/etesevimab in outpatients with COVID-19 infected by the Gamma variant, according to a study presented at ECCMID 2021.
Delafloxacin is noninferior to best available therapies (BAT) for acute bacterial skin and skin structure infections (ABSSSI), particularly in the subset of surgical site infections (SSI), according to the results of the phase IIIb/IV, observer-blinded DRESS study presented at ECCMID 2021.